Lecap Asset Management Ltd. Sells 1,767 Shares of Repligen Co. (NASDAQ:RGEN)

Lecap Asset Management Ltd. trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 13.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,264 shares of the biotechnology company’s stock after selling 1,767 shares during the period. Lecap Asset Management Ltd.’s holdings in Repligen were worth $1,676,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of RGEN. Toronto Dominion Bank increased its holdings in Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 89 shares during the last quarter. Diversified Trust Co lifted its holdings in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 106 shares during the last quarter. CWM LLC increased its holdings in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Repligen by 24.0% in the third quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 115 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Repligen Price Performance

Shares of RGEN stock opened at $137.48 on Thursday. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $144.24 and a 200 day simple moving average of $147.63. The company has a market cap of $7.68 billion, a P/E ratio of 549.92, a P/E/G ratio of 4.24 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.53 EPS. On average, sell-side analysts forecast that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.